Vaccines against malaria - An update

FEBS Journal

Volumn 274, Issue 18, 2007, Pages 4680-4687

  Matuschewski, Kai ^a   Mueller, Ann Kristin ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Attenuated live parasite; Malaria; MSP1; Plasmodium; Protective immunity; RTS S; Severe disease; Transmission blocking antibodies; Vaccine; var2CSA

Indexed keywords

MALARIA VACCINE; SUBUNIT VACCINE;

HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; MALARIA; MORBIDITY; PLASMODIUM; PREVENTION AND CONTROL; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; HUMANS; MALARIA; MALARIA VACCINES; VACCINES, SUBUNIT;

EID: 34548381803     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2007.05998.x     Document Type: Short Survey

References (52)

1. World Health Organization (2005) World Malaria Report 2005. WHO, Geneva.
2. Matuschewski K (2006) Getting infectious: formation and maturation of Plasmodium sporozoites in the Anopheles vector. Cell Microbiol 8, 1547 1556.
3. Prudencio M, Rodriguez A Mota MM (2006) The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol 4, 849 856.
4. Marsh K Kinyanjui S (2006) Immune effector mechanisms in malaria. Parasite Immunol 28, 51 60.
5. Rieckmann KH (2006) The chequered history of malaria control: are new and better tools the ultimate answer? Ann Trop Med Parasitol 100, 647 662.
6. Richie TL Saul A (2002) Progress and challenges for malaria vaccines. Nature 415, 694 701.
7. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG et al. (2004) Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 71 (Suppl. 2 239 247.
8. Good MF (2005) Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol 21, 29 34.
9. Matuschewski K (2006) Vaccine development against malaria. Curr Opin Immunol 18, 449 457.
10. Malkin E, Dubovsky F Moree M (2006) Progress towards the development of malaria vaccines. Trends Parasitol 22, 292 295.
11. Cohen S, McGregor GI Carrington S (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192, 733 737.
12. Graves P Gelband H (2006) Vaccines for preventing malaria (SPf66). Cochrane Database System Rev CD005966.
13. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet 364, 1411 1420.
14. Mackintosh CL, Beeson JG Marsh K (2004) Clinical features and pathogenesis of severe malaria. Trends Parasitol 20, 597 603.
15. Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, Tascon R, Franco A, Murillo LA, Ponton G et al. (1988) A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332, 158 161.
16. Kumar KA, Sano G-I, Boscardin S, Nussenzweig RS, Nussenzweig MC, Zavala F Nussenzweig V (2006) The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444, 937 940.
17. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, Bojang KA, Oduola AMJ, Kremsner PG, Arnot DE et al. (2000) A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 6, 689 692.
18. Heppner DG, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U et al. (2005) Towards an RTS,S-based multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23, 2243 2250.
19. Bojang KA (2006) RTS,S/AS02A for malaria. Expert Rev Vaccines 5, 611 615.
20. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M et al. (1997) A preliminary evaluation of a recombinant cicrumsporozoite vaccine against Plasmodium falciparum malaria. N Engl J Med 336, 86 91.
21. Kester KE, McKinney DA, Torniepoth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG et al. (2001) Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183, 640 647.
22. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Wellde BT, White K, Sun P, Schwenk R et al. (2007) A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. Vaccine 25, 5359 5366.
23. Bojang KA, Milligan PJM, Pinder M, Vigneron L, Alloueche A, Kester K, Ballou WR, Conway DJ, Reece WHH, Gothard P et al. (2001) Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomized trial. Lancet 358, 1927 1934.
24. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q et al. (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomized control trial. Lancet 366, 2012 2018.
25. Enosse S, Dobaño C, Quelhas D, Aponte JJ, Lievens M, Leach A, Sacarlal J, Greenwood B, Milman J, Dubovsky F et al. (2006) RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clinical Trials 1, e5.
26. Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Nije F, Kassanga A, Leach A, Milman J et al. (2005) Safety and immunogenicity of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23, 4148 4157.
27. Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, Mandomando I, Espasa M, Bevilacqua C, Leach A, Dubois MC et al. (2007) Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Trop Med Int Health 12, 37 46.
28. Calvo-Calle JM, Oliveira GA, Watta CO, Soverow J, Parra-Lopez C Nardin EH (2006) A linear peptide containing mininmal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge. Infect Immun 74, 6929 6939.
29. Herrera S, Bonelo A, Perlaza BL, Fernandez OL, Victoria L, Lenis AM, Soto L, Hurtado H, Acuna LM, Velez JD et al. (2005) Safety and elicitation of humoral and cellular responses in Colombian malaria-naïve volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 73 (Suppl. 5 3 9.
30. Siddiqui WA, Tam LQ, Kramer KJ, Hui GSN, Case SE, Yamaga KM, Chang SP, Chan EBT Kan S-C (1987) Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci USA 84, 3014 3018.
31. Pan W, Ravot E, Tolle R, Frank R, Mosbach R, Turbachova I Bujard H (1999) Vaccine candidate MSP-1 from Plasmodium falciparum: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells. Nucleic Acids Res 27, 1094 1103.
32. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, Apollo OJ, Allen OG, Tucker K, Soisson LA, Diggs C et al. (2006) Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clinical Trials 1, e32.
33. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Stewart VA, Angov E et al. (2006) Safety and allele-specific immunogenicity of a malaria vaccine in mammalian adults: results of a phase I randomized trial. PLoS Clinical Trials 1, e34.
34. Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, Miller LH Stowers AW (2002) Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis 185, 657 664.
35. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S, Audran R, Bouzidi A, Oeuvray C Roussilhon C (2005) A malaria vaccine that elicits in human antibodies able to kill Plasmodium falciparum. PLoS Medicine 2, e344.
36. Polley SD, Tetteh KKA, Lloyd JM, Akpogheneta OJ, Greenwood BM, Bojang KA Conway DJ (2007) Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 195, 279 287.
37. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, Bodescot M, Rubinstein E, Hannoun L, Charoenvit Y, Kocken CH et al. (2004) A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 279, 9490 9496.
38. Kyes S, Horrocks P Newbold C (2001) Antigenic variation at the infected red cell surface in malaria. Annu Rev Microbiol 55, 673 707.
39. Salanti A, Staalsoe T, Lavstsen T, Jensen AT, Sowa MP, Arnot DE, Hviid L Theander TG (2003) Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 49, 179 191.
40. Salanti A, Dahlbäck M, Turner L, Nielsen MA, Barford L, Magistrado P, Jensen ATR, Lavstsen T, Ofori MF, Marsh K et al. (2004) Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 200, 1197 1203.
41. Fried M, Nosten F, Brockman A, Brabin BJ Duffy PE (1998) Maternal antibodies block malaria. Nature 395, 851 852.
42. Nussenzweig RS, Vanderberg J, Most H Orton C (1967) Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 216, 160 162.
43. Luke TC Hoffman SL (2003) Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 206, 3803 3808.
44. Mueller A-K, Labaied M, Kappe SHI Matuschewski K (2005) Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433, 164 167.
45. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C et al. (2002) Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185, 1155 1164.
46. Jobe O, Lumsden J, Mueller A-K, Williams J, Silva-Rivera H, Kappe SHI, Schwenk RJ, Matuschewski K Krzych U (2007) Genetically-attenuated Plasmodium berghei liver-stages induce sterile protracted protection that is mediated by MHC class I-dependent IFN-γ producing CD8+ T cells. J Infect Dis 196, 599 607.
47. Moorthy VS, Imoukuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM Hill AS (2004) A randomized, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Medicine 1, e33.
48. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S, Keating S, Lang T, Lowe B, Gikonyo C et al. (2006) A phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clinical Trials 1, e29.
49. Wang Q, Brown S, Roos DS, Nussenzweig V Bhanot P (2004) Transcriptome of axenic liver stages of Plasmodium yoelii. Mol Biochem Parasitol 137, 161 168.
50. Tomas AM, Margos G, Dimopoulos G, van Lin LH, de Koning-Ward TF, Sinha R, Lupetti P, Beemtsma AL, Rodriguez MC, Karras M et al. (2001) P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. EMBO J 20, 3975 3983.
51. Carter R, Graves PM, Quakyi IA Good MF (1989) Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. J Exp Med 169, 135 147.
52. Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, Shiloach J, Robbins JB Schneerson R (2007) Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci USA 104, 293 298.